Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RIGL | US
-0.55
-3.32%
Healthcare
Biotechnology
30/06/2024
04/10/2024
16.04
16.44
16.46
15.82
Rigel Pharmaceuticals Inc. a biotechnology company engages in discovering developing and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco California.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
103.7%1 month
73.6%3 months
78.0%6 months
80.0%-
204.08
31.64
-2.02
0.47
-5.02
2.30
-0.10
-7.52M
282.22M
282.22M
-
1.21
-47.90
42.30
-699.05
4.62
2.91
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.62
Range1M
4.53
Range3M
9.70
Rel. volume
0.31
Price X volume
995.44K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PEPG | PEPG | Biotechnology | 9.3 | 303.08M | 2.88% | n/a | 12.52% |
Kamada Ltd | KMDA | Biotechnology | 5.2 | 298.89M | -0.57% | 20.04 | 3.41% |
STROUDS INC | STRO | Biotechnology | 3.61 | 295.89M | 2.85% | n/a | 125.14% |
Aviragen Therapeutics Inc | AVIR | Biotechnology | 3.46 | 292.10M | 2.67% | n/a | 0.43% |
THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 5.51 | 291.89M | 5.15% | n/a | 35.68% |
Ocugen Inc | OCGN | Biotechnology | 1.01 | 290.74M | 4.12% | n/a | 40.56% |
Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 8.66 | 286.31M | -0.69% | n/a | 6.58% |
Design Therapeutics Inc. Common Stock | DSGN | Biotechnology | 5 | 283.10M | 0.60% | n/a | 1.03% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 6.46 | 279.81M | 3.69% | n/a | 31.63% |
Akebia Therapeutics Inc | AKBA | Biotechnology | 1.33 | 279.68M | -0.75% | n/a | -309.96% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.02 | 0.76 | Cheaper |
Ent. to Revenue | 2.30 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 31.64 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 77.95 | 74.67 | Par |
Debt to Equity | -2.02 | -1.82 | Cheaper |
Debt to Assets | 0.47 | 0.26 | Expensive |
Market Cap | 282.22M | 3.73B | Emerging |